Humacyte Inc. (HUMA)
Цена, главные цифры и свежие новости — всё на одной странице.
Humacyte Inc. (HUMA): цена акции, анализ и данные
| Бид | 0.51 |
| Рыночная капитализация | 180.04M |
| Выручка (TTM) | 2.12M |
| Чистая прибыль (TTM) | -96.67M |
| 2.47 | |
| -0.52 | |
| n/a | |
| -2.62 | |
| P/B (TTM) | 12.46 |
| P/S (TTM) | 84.88 |
| Дата отчёта | Nov 12, 2026 |
| Аск | 0.88 |
| Объём торгов | 5,905,985 |
| Ср. объём (20д) | 11,136,119 |
| Открытие | 0.66 |
| Пред. закрытие | 0.66 |
| Диапазон дня | 0.66 - 0.73 |
| Диапазон за 52 недели | 0.53 - 2.55 |
| Аналитики | n/a |
| Целевая цена | n/a |
| Дивиденды | n/a |
| Дата отсечки | n/a |
О компании HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign...
Финансовые результаты
В 2025 году выручка Humacyte составила 2.04M — это рост на undefined% к прошлогодним 0. Прибыль составила -40.83M — это снижение на -72.54%.
Финансовая отчётностьСюрприз в отчёте
- Выручка $495K ниже прогноза на $0, при -4.26% снижении год к году.
- EPS -0.16 ниже прогноза на -0.06, при 33.33% рост год к году.
Аналитики ждут выручку ... Улучшить тариф
2 недель назад · Simply Wall St.
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative HoldsHumacyte earnings update and stock context Humacyte (HUMA) reported second quarter 2026 results that included revenue of US$0.406 million and a net loss of US$36.8 million, alongside recent Nasdaq com...
2 недель назад · Simply Wall St.
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% FallHumacyte stock has had a very rough run over the last several years, and current valuation checks now lean toward the shares looking expensive rather than like a clear bargain. Humacyte has declined 9...
2 недель назад · Simply Wall St.
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In WomenHumacyte (NasdaqGS:HUMA) reported Phase 3 dialysis access data showing its acellular tissue engineered vessel outperformed standard of care for female patients. The company plans to file a supplementa...